BioLineRx Ltd.BLRX
Price (close)
$2.60
Market cap
$11.4M
P/E
—
Revenue (FY)
$1.2M
Net income
-$8.0M
Dividend yield
—
1-year total return
-31.4%
Net margin
-680.2%
Revenue growth
-95.9%
Debt / equity
—
What BioLineRx Ltd. does.
in oncology and rare diseases. Our first approved product, APHEXDA® (motixafortide), a novel peptide for the treatment of stem-cell
mobilization and solid tumors, with an indication in the United States for stem cell mobilization for autologous transplantation
in multiple myeloma, is being developed and commercialized by Ayrmid Pharma Ltd. (globally, excluding Asia) and Gloria, (in Asia). We
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $4.8M | $28.9M | $1.2M |
| Net income | -$30.0M | -$27.1M | -$25.0M | -$60.6M | -$9.2M | -$8.0M |
| Free cash flow | -$23.2M | -$23.7M | -$26.4M | -$22.7M | -$43.9M | -$8.1M |
More on BLRX.
- BioLineRx Ltd. summary
- BioLineRx Ltd. financial statements
- BioLineRx Ltd. key metrics
- BioLineRx Ltd. health scores and style box
- BioLineRx Ltd. earnings
- BioLineRx Ltd. dividends
- BioLineRx Ltd. valuation
- BioLineRx Ltd. ownership and insiders
- BioLineRx Ltd. peers
Figures from BioLineRx Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.